Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-base (daratumumab + lenalidomide/pomalidomide) maintenance after ASCT in high-risk multiple myeloma
ChiCTR2500097978Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab, lenalidomide and pomalidomide in multiple myeloma (MM), sponsored by West China Hospital of Sichuan University. Primary endpoints: Progression-free survival, Overall response rate and 1 more. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
daratumumablenalidomidepomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500097978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097978.